摘要
目的探究对冠心病不稳定型心绞痛患者进行法舒地尔联合辅酶Q10治疗的效果。方法 128例冠心病不稳定型心绞痛患者,随机分为实验组和对照组,每组64例。两组患者均采用常规治疗,在此基础上,实验组患者采用法舒地尔联合辅酶Q10治疗,对照组患者采用法舒地尔的治疗。比较两组患者的治疗效果、治疗前后白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平。结果实验组患者治疗总有效率为96.88%,显著高于对照组的76.56%,差异具有统计学意义(P<0.05)。治疗后,两组患者IL-6、TNF-α水平均较本组治疗前降低,且实验组以上指标的水平明显低于对照组,差异具有统计学意义(P<0.05)。结论对冠心病不稳定性型心绞痛患者采用法舒地尔联合辅酶Q10进行治疗,取得了显著的治疗效果,可以在临床推广使用。
Objective To investigate the efficacy of Fasudil combined with Coenzyme Q10 in the treatment of unstable angina pectoris of coronary heart disease. Methods A total of 128 patients with unstable angina pectoris of coronary heart disease were randomly divided into experimental group and control group, 64 eases in each group. Patients of the two groups were given conventional therapy, on this basis, patients in the experimental group were treated with Fasudil combined with Coenzyme QIO, patients in the control group were treated with Fasudil. The therapeutic effect, the levels of interleukin-6 （IL-6） and tumor necrosis factor- α （TNF-α） before and after treatment between the two groups were compared. Results The total effective rate of the experimental group was 96.88%, which was significantly higher than 76.56% of the control group, the difference was statistically significant （P〈0.05）. After treatment, the levels of IL-6 and TNF- α in the two groups were significantly lower than those before treatment, and above indexes in the experimental group were significantly lower than those in the control group, the differences were statistically significant （P〈0.05）. Conclusion The application of Fasudil combined with Coenzyme Q10 in the treatment of unstable angina pectoris of coronary heart disease has achieved remarkable therapeutic effect and can be popularized in clinical practice.
作者
葛盛福
GE Sheng-fu(Shenyang Emergency Center,Shenyang 110006,China)
出处
《中国实用医药》
2018年第26期89-90,共2页
China Practical Medicine
关键词
辅酶Q10
法舒地尔
冠心病
不稳定型心绞痛
Coenzyme Q10
Fasudil
Coronary heart disease
Unstable angina pectoris
